Oliceridine (TRV130) Has a Differentiated Profile of G Protein and β-arrestin Signaling Versus Select Opioids

被引：0
|
作者：
Cowan, Conrad [1 ]
Gowen-MacDonald, William [1 ]
Graczyk, Thomas [2 ]
Lark, Mike [1 ]
机构：
[1] Trevena Inc, King Of Prussia, PA USA
[2] Teva Pharmaceut, Petah Tiqwa, Israel
来源：
PAIN MANAGEMENT NURSING | 2017年 / 18卷 / 02期
关键词：
D O I：
10.1016/j.pmn.2017.02.193
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
I3
引用
收藏
页码：72 / 72
页数：1
相关论文
共 26 条
  • [1] OLICERIDINE (TRV130), A NOVEL μ RECEPTOR G PROTEIN PATHWAY SELECTIVE (μ-GPS) MODULATOR, HAS A DIFFERENTIATED PROFILE OF G PROTEIN AND β-ARRESTIN SIGNALING VERSUS OPIOIDS
    Gowen-MacDonald, W.
    Graczyk, T.
    Lark, M.
    Cowan, C.
    Gan, T. J.
    ANESTHESIA AND ANALGESIA, 2016, 122
  • [2] THE EFFECT OF A G-PROTEIN BIASED LIGAND, TRV130, ON OPIOID-INDUCED CONSTIPATION
    Jacob, Joanna C.
    David, Bethany
    Khan, Aliyeen
    Dewey, William L.
    Akbarali, Hamid I.
    GASTROENTEROLOGY, 2018, 154 (06) : S758 - S758
  • [3] How Oliceridine (TRV-130) Binds and Stabilizes a μ-Opioid Receptor Conformational State That Selectively Triggers G Protein Signaling Pathways
    Schneider, Sebastian
    Provasi, Davide
    Filizola, Marta
    BIOCHEMISTRY, 2016, 55 (46) : 6456 - 6466
  • [4] Discovery of TRV130, a G protein biased agonist of the μ-opioid receptor, for the treatment of acute severe pain
    Crombie, Aimee
    Chen, Xiao-Tao
    Pitis, Philip
    Liu, Guodong
    Yuan, Catherine
    Gotchev, Dimitar
    Yamashita, Dennis
    Violin, Jonathan
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
  • [5] Can oliceridine (TRV130), an ideal novel. receptor G protein pathway selective (μ-GPS) modulator, provide analgesia without opioid-related adverse reactions?
    Ok, Hwoe Gyeong
    Kim, Su Young
    Lee, Su Jung
    Kim, Tae Kyun
    Huh, Billy K.
    Kim, Kyung Hoon
    KOREAN JOURNAL OF PAIN, 2018, 31 (02): : 73 - 79
  • [6] The G Protein Signal-Biased Compound TRV130; Structures, Its Site of Action and Clinical Studies
    Miyano, Kanako
    Manabe, Sei
    Komatsu, Akane
    Fujii, Yuriko
    Mizobuchi, Yusuke
    Uezono, Eiko
    Ohshima, Kaori
    Nonaka, Miki
    Kuroda, Yui
    Narita, Minoru
    Uezono, Yasuhito
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2020, 20 (31) : 2822 - 2829
  • [7] A randomized, Phase IIb study investigating oliceridine (TRV130), a novel μ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty
    Singla, Neil
    Minkowitz, Harold S.
    Soergel, David G.
    Burt, David A.
    Subach, Ruth Ann
    Salamea, Monica Y.
    Fossler, Michael J.
    Skobieranda, Franck
    JOURNAL OF PAIN RESEARCH, 2017, 10 : 2413 - 2424
  • [8] A RANDOMIZED, PLACEBO- AND ACTIVE-CONTROLLED PHASE 2B STUDY INVESTIGATING OLICERIDINE (TRV130), A NOVEL μ RECEPTOR G PROTEIN PATHWAY SELECTIVE (μ-GPS) MODULATOR
    Minkowitz, H.
    Soergel, D.
    Burt, D.
    Skobieranda, F.
    Gan, T. J.
    ANESTHESIA AND ANALGESIA, 2016, 122
  • [9] RAPID ONSET OF PAIN RELIEF WITH OLICERIDINE (TRV130), A NOVEL μ RECEPTOR G PROTEIN PATHWAY SELECTIVE (μ-GPS) MODULATOR, VS. MORPHINE: A PHASE 2A/B STUDY ANALYSIS
    Viscusi, E.
    Webster, L.
    Soergel, D.
    Burt, D. A.
    Skobieranda, F.
    Gan, T. J.
    ANESTHESIA AND ANALGESIA, 2016, 122
  • [10] Respiratory safety signal with oliceridine (TRV130), a novel μ receptor G protein pathway selective modulator (μ-GPS), vs morphine: a safety analysis of a Phase 2b randomized clinical trial
    Singla, N.
    Minkowitz, H.
    Soergel, D.
    Burt, D.
    Skobieranda, F.
    JOURNAL OF PAIN, 2016, 17 (04): : S82 - S82
123